Phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in progressive or recurrent ovarian cancer

Journal of Clinical Oncology

Volumn 26, Issue 6, 2008, Pages 890-896

  Ferrandina, Gabriella ^a   Ludovisi, Manuela ^a   Lorusso, Domenica ^a   Pignata, Sandro ^a   Breda, Enrico ^a   Savarese, Antonella ^a   Del Medico, Pietro ^a   Scaltriti, Laura ^a   Katsaros, Dionyssios ^a   Priolo, Domenico ^a   Scambia, Giovanni ^a  

^a CATHOLIC UNIVERSITY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

DOXORUBICIN; GEMCITABINE; PACLITAXEL; PLATINUM; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIBIOTIC; ANTINEOPLASTIC ANTIMETABOLITE; DEOXYCYTIDINE; DRUG DERIVATIVE; MACROGOL DERIVATIVE;

ADULT; AGED; ALLERGIC REACTION; ANEMIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RECURRENCE; CLINICAL ASSESSMENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HAND FOOT SYNDROME; HUMAN; LEUKOPENIA; MAJOR CLINICAL STUDY; MUCOSA INFLAMMATION; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OVARY CANCER; OVERALL SURVIVAL; PATIENT COMPLIANCE; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT RESPONSE; VOMITING; COMPARATIVE STUDY; DISEASE COURSE; DRUG ADMINISTRATION; ITALY; KAPLAN MEIER METHOD; MALE; MIDDLE AGED; OVARY TUMOR; TREATMENT OUTCOME; TUMOR RECURRENCE;

ADULT; AGED; ANTIBIOTICS, ANTINEOPLASTIC; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; DEOXYCYTIDINE; DISEASE PROGRESSION; DOXORUBICIN; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; ITALY; KAPLAN-MEIERS ESTIMATE; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; OVARIAN NEOPLASMS; POLYETHYLENE GLYCOLS; QUALITY OF LIFE; TREATMENT OUTCOME;

EID: 39749113438     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2007.13.6606     Document Type: Article

References (33)

1. Eisenkop S, Spirtos NM, Friedman RL, et al: Relative influences of tumor volume before surgery and the cytoreductive outcome on survival for patients with advanced ovarian cancer: A prospective study. Gynecol Oncol 90:390-396, 2003
2. McGuire WP, Hoskins WJ, Brady MF, et al: Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 334:1-6, 1996
3. Ozols RF, Bundy BN, Greer BE, et al: Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: A Gynecologic Oncology Group study. J Clin Oncol 21:3194-3200, 2003
4. Jemal A, Siegel R, Ward E, et al: Cancer statistics, 2006. CA Cancer J Clin 56:106-130, 2006
5. Ozols R: Systemic therapy for ovarian cancer: Current status and new treatments. Semin Oncol 33:S3-S11, 2006 (suppl)
6. Salzberg M, Thurlimann B, Bonnefois H, et al: Current concepts of treatment strategies in advanced or recurrent ovarian cancer. Oncology 68:293-298, 2005
7. Armstrong D: Relapsed ovarian cancer: Challenges and management strategies for a chronic disease. Oncologist 7:20-28, 2007
8. Herzog TJ: The current treatment of recurrent ovarian cancer. Curr Oncol Rep 8:448-454, 2006
9. ten Bokkel Huinink W, Lane SR, Ross GA: Long term survival in a phase III, randomized study of topotecan versus paclitaxel in advanced epithelial ovarian carcinoma. Ann Oncol 15:100-103, 2004
10. O'Byrne KJO, Bliss P, Graham JD, et al: A phase III study of Doxil/Caelyx versus paclitaxel in platinum-treated, taxane naïve relapsed ovarian cancer. Proc Am Soc Clin Oncol 21:203a, 2002 (abstr 808)
11. Gordon AN, Fleagle JT, Guthrie D, et al: Recurrent epithelial ovarian carcinoma: A randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol 19:3312-3322, 2001
12. Mutch DG, Orlando M, Goss T, et al: Randomized phase III trial of gemcitabine compared to pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer. J Clin Oncol 25:2811-2818, 2007
13. Gordon AN, Tonda M, Sun S, et al: Long term survival advantage for women treated with pegylated liposomal doxorubicin versus topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer. Gynecol Oncol 95:1-8, 2004
14. D'Agostino G, Amant F, Berteloot P, et al: Phase II study of gemcitabine in recurrent platinum-and paclitaxel-resistant ovarian cancer. Gynecol Oncol 88:266-269, 2003
15. Ferrandina G, Paris I, Ludovisi M, et al: Gemcitabine and liposomal doxorubicin in the salvage treatment of ovarian cancer: Updated results and long-term survival. Gynecol Oncol 98:267-273, 2005
16. Pectasides D, Psyrri A, Pectasides M, et al: Optimal therapy for platinum resistant recurrent ovarian cancer: Doxorubicin, gemcitabine or topotecan? Expert Opin Pharmacother 7:975-987, 2006
17. Rose PG, Maxson JH, Fusco N, et al: Liposomal doxorubicin in ovarian, peritoneal, and tubal carcinoma: A retrospective comparative study of single-agent dosages. Gynecol Oncol 82:323-328, 2001
18. 2) in platinum/paclitaxel-refractory ovarian and fallopian tube cancers and primary carcinoma of the peritoneum. Gynecol Oncol 78:369-372, 2000
19. Campos SM, Penson RT, Mays AR, et al: The clinical utility of liposomal doxorubicin in recurrent ovarian cancer. Gynecol Oncol 81:206-212, 2001
20. 2) in the treatment of gynecologic cancers. Gynecol Oncol 97:374-378, 2005
21. Parmar MK, Ledermann JA, Colombo N, et al: Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: The ICON4/AGO-OVAR-2.2 trial. Lancet 361:2099-2106, 2003
22. Pfisterer J, Plante M, Vergote I, et al: Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: An intergroup trial of the AGO-OVAR, the NCIC CTG, and EORTC GCG. J Clin Oncol 24:4699-4707, 2006
23. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92:205-216, 2000
24. Rustin GJ: Use of CA-125 to assess response to new agents in ovarian cancer trials. J Clin Oncol 21:187S-193S, 2003 (suppl 10)
25. National Cancer Institute: Cancer Therapy Evaluation Program: Common Toxicity Criteria. Version 2.0, April 30, 1999. http://ctep.info.nih.gov
26. Aaronson NK, Ahmedzai S, Bergman B, et al: The European Organization for Research and Treatment of Cancer QLQ-C30: A quality of life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85:365-376, 1993
27. Kaplan E, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
28. Mantel N: Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 50:163-170, 1966
29. Cox DR: Regression models and life tables. J R Stat Soc B 34:187-220, 1972
30. Gossner HG, Coleman RL, Mutch DG, et al: Ca-125 response in patients with recurrent ovarian or peritoneal cancer treated with pegylated liposomal doxorubicin or topotecan. Gynecol Oncol 103:212-218, 2006
31. Coleman RL, Gordon A, Barter J, et al: Early changes in CA125 after treatment with pegylated liposomal doxorubicin or topotecan do not always reflect best response in recurrent ovarian cancer patients. Oncologist 12:72-78, 2007
32. Sehouli J, Oskay-Ozcelik G, Kuhne JK, et al: Biweekly pegylated liposomal doxorubicin in patients with relapsed ovarian cancer: Results of a multicenter phase II trial. Ann Oncol 17:957-961, 2006
33. Smiths DH, Adams JR, Johnston SRD, et al: A comparative economic analysis of pegylated liposomal doxorubicin versus topotecan in ovarian cancer in the USA and the UK. Ann Oncol 13:1590-1597, 2002